Stocks and Investing Stocks and Investing
Thu, September 19, 2024

Gregory Renza Reiterated (VRDN) at Buy and Held Target at $44 on, Sep 19th, 2024


Published on 2024-10-28 14:20:52 - WOPRAI, Gregory Renza
  Print publication without navigation


Gregory Renza of RBC Capital, Reiterated "Viridian Therapeutics, Inc." (VRDN) at Buy and Held Target at $44 on, Sep 19th, 2024.

Gregory has made no other calls on VRDN in the last 4 months.



There are 7 other peers that have a rating on VRDN. Out of the 7 peers that are also analyzing VRDN, 0 agree with Gregory's Rating of Hold.



These are the ratings of the 7 analyists that currently disagree with Gregory


  • Richard Law of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $31 on, Thursday, September 12th, 2024
  • Serge Belanger of "Needham" Maintained at Strong Buy with Increased Target to $38 on, Wednesday, September 11th, 2024
  • Douglas Tsao of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $27 on, Tuesday, September 10th, 2024
  • Julian Harrison of "BTIG" Maintained at Strong Buy with Increased Target to $56 on, Tuesday, September 10th, 2024
  • Leland Gershell of "Oppenheimer" Reiterated at Buy with Decreased Target to $28 on, Monday, August 12th, 2024
  • Laura Chico of "Wedbush" Reiterated at Buy and Held Target at $42 on, Monday, July 29th, 2024
  • Andy Chen of "Wolfe Research" Initiated at Buy on, Tuesday, June 11th, 2024
Contributing Sources